While progress has been made to influence the treatment landscape of Alzheimer’s disease, gaps to widespread therapeutic availability and imaging remain.
Novartis continues to navigate a decisive period as newer portfolio assets start to offset patent pressures.
BMS enhances its AI computing power as big pharma race to stay competitive within the shifting global landscape.
An analysis of GlobalData’s Drug Pricing (POLI) & HTA database shows no HTA outcome for Ojemda in the wake of the JCA review.
The companies aim to enable simplified dosing and delivery methods for patients receiving treatment for MPNs.
C-CAR168 is aimed at depleting both autoreactive B cells and antibody-producing plasma cells.
